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Background: In a previous proteomics study using pooled cerebrospinal fluid (CSF) samples, we proposed
apolipoprotein AI, apolipoprotein AIV, vitronectin, plasminogen, semaphorin 7A, and ala-β-his-dipeptidase as
candidate biomarkers associated with the conversion to clinically definite multiple sclerosis (CDMS) in patients
with clinically isolated syndromes (CIS). Here, we aimed to validate these results in individual CSF samples using
alternative techniques.
Methods: In a first replication study, levels of apolipoproteins AI and AIV, vitronectin, and plasminogen were
measured by ELISA in CSF and serum of 56 CIS patients (29 patients who converted to CDMS (MS converters)
and 27 patients who remained with CIS during follow-up (MS non-converters)) and 26 controls with other neurological
disorders. Semaphorin 7A and ala-β-his-dipeptidase levels were determined by selected reaction monitoring (SRM) in
CSF of 36 patients (18 MS converters, 18 non-converters) and 20 controls. In a second replication study, apolipoprotein
AI levels were measured by ELISA in CSF of 74 CIS patients (47 MS converters, 27 non-converters) and 50 individual
controls, and levels of semaphorin 7A and ala-beta-his-dipeptidase were determined by SRM in 49 patients (24 MS
converters, 25 non-converters) and 22 controls.
Results: CSF levels of apolipoprotein AI were increased (P = 0.043) and levels of semaphorin 7A and ala-β-his-dipeptidase
decreased (P = 4.4 × 10−10 and P = 0.033 respectively) in MS converters compared to non-converters. No significant
differences were found in serum levels for apolipoproteins AI and AIV, vitronectin, and plasminogen. Findings
with semaphorin 7A and ala-β-his-dipeptidase were also validated in the second replication study, and CSF levels
for these two proteins were again decreased in MS converters versus non-converters (P = 1.2 × 10−4 for semaphorin
7A; P = 3.7 × 10−8 for ala-β-his-dipeptidase). Conversely, apolipoprotein AI findings were not replicated and CSF levels
for this protein did not significantly differ between groups. Furthermore, CSF semaphorin 7A levels were negatively
associated with the number of T2 lesions at baseline and one-year follow-up.
Conclusions: These results validate previous findings for semaphorin 7A and ala-β-his-dipeptidase, and suggest that
these proteins play a role as CSF biomarkers associated with the conversion to CDMS in CIS patients.
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In patients with clinically isolated syndromes (CIS), mag-
netic resonance imaging (MRI) abnormalities and the
presence of immunoglobulin G (IgG) oligoclonal bands in
cerebrospinal fluid (CSF) are important predictors of later
conversion to multiple sclerosis (MS) [1-4]. With the aim
to identify additional molecular biomarkers associated
with the conversion to MS, we recently conducted a mass
spectrometry-based proteomic study in pooled CSF sam-
ples from patients with CIS who converted to clinically
definite MS (CDMS) and patients who remained with CIS
[5]. Three candidates, chitinase 3-like 1 (CHI3L1), cerulo-
plasmin, and vitamin D-binding protein were selected for
validation in individual CSF samples, and CHI3L1 findings
were confirmed in additional cohorts of CIS patients [5].
In this initial screening proteomic study, other proteins
were identified and proposed to be candidate biomarkers
associated with conversion to MS: apolipoprotein AI
(apoAI), apolipoprotein AIV (apoAIV), vitronectin, and
plasminogen were found to be upregulated, and sema-
phorin 7A (sema7A) and ala-beta-his-dipeptidase (CNDP1)
were found to be downregulated in CSF pools of CIS
patients who converted to CDMS [5]. In the present
study, we pursued the validation of these proteins as
biomarkers using different techniques in individual CSF
samples from CIS patients classified according to their
conversion (or lack of ) to CDMS.
Materials and methods
Patients
Individuals included in the study were part of a cohort
of patients with CIS recruited at the Centre d’EsclerosiTable 1 Clinical information and CSF characteristics of CIS pa
Cohort 1* - ELISA studies
Characteristics CIS→ CIS CIS→ CDMS
n 27 29
Age (years)a 28.1 (9.6) 27.4 (6.3)
Female/male (% female) 20/7 (74.1) 20/9 (69.0)
Follow-up time (years)a 8.2 (4.2) 8.6 (3.3)
Clinical presentation
Optic neuritis 15 (55.6) 8 (27.6)
Brainstem 4 (14.8) 7 (24.1)
Spinal 5 (18.5) 8 (27.6)
Others 3 (11.1) 6 (20.7)
CSF cellsb 0.5 (0-5.0) 2.0 (0-9.0)
Proteins (mg/dL)b 33.0 (24.0-43.0) 37.0 (26.8-57.3)
*Cohort 1 was used for the determination of CSF and serum levels of apolipoprotei
was used for the quantification of CSF levels of semaphorin 7A and ala-beta-his-dip
were present in both cohorts of patients. aData are expressed as mean (standard de
obtained following comparisons between CIS→ CIS patients and CIS→ CDMS patie
Mann-Whitney U test (remaining variables). Proteins (mg/dL) refers to protein conce
isolated syndromes, CSF, cerebrospinal fluid.Múltiple de Catalunya (Cemcat, Barcelona, Spain) from
1995 onwards. The study was approved by the local eth-
ics committee (PR(AG)28/2007). Clinical, CSF, and MRI
evaluations have been previously described elsewhere
[2]. Patients with CIS were classified according to the
following criteria: no conversion to CDMS during the
follow-up period, negative IgG oligoclonal bands, and 0
Barkhof criteria at a baseline brain MRI (CIS→CIS
group); or conversion to CDMS, presence of IgG oligo-
clonal bands, and an abnormal brain MRI at baseline
(2, 3, or 4 Barkhof criteria) (CIS→CDMS group). A sum-
mary of clinical information and CSF characteristics of
CIS patients included in the study is shown in Table 1.
Since 2001, a baseline brain MRI scan was performed at
the time of the CIS and at 3 to 5 months from disease
onset. Follow-up MRI scans were performed at 12 months
and every five years after the CIS. The scans were obtained
on a 1.5 Tesla (T) magnet until 2009 and on a 3.0 T with
a standard head coil since 2010. The following sequences
of the brain were performed in each patient: transverse
proton density/T2-weighted fast spin-echo, transverse
T2-weighted fast-fluid-attenuated-inversion recovery,
and transverse T1-weighted spin-echo (600/12/2 (TR/
TE/acquisitions)). The transverse T1-weighted sequence
was repeated in those patients with demonstrated focal
white matter lesions on T2-weighted sequences after
gadolinium (Gd) injection (0.1 mmol/kg; scan delay,
5 minutes). The number and location of T2 lesions,
number of gadolinium-enhancing lesions, and number
of new T2 lesions on the brain were scored. For the
number of T2 lesions, three different categories were
considered: 0, 1 to 9, and 10 or more lesions.tients included in the study
Cohort 2** - proteomic studies
P values CIS→ CIS CIS→ CDMS P values
- 18 18 -
0.724 31.7 (7.3) 30.2 (5.9) 0.308
0.672 13/5 (72.2) 13/5 (72.2) 1
0.819 6.1 (3.6) 8.8 (2.7) 0.098
0.206 9 (50.0) 3 (16.7) 0.152
2 (11.1) 5 (27.8)
3 (16.7) 6 (33.3)
4 (22.2) 4 (22.2)
0.337 0 (2.4-3.5) 4.0 (0-11.5) 0.059
0.391 32.5 (23.7-41.5) 29.5 (24.0-51.8) 0.705
n AI, apolipoprotein AIV, vitronectin, and plasminogen by ELISA. **Cohort 2
eptidase by selected reaction monitoring (SRM). A total of 23 (63.9%) patients
viation). bData are expressed as median (interquartile range). P values were
nts by means of the chi-square test (gender and clinical presentation) and the
ntration in mg/dL. CDMS, clinically definite multiple sclerosis; CIS, clinically
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apolipoprotein AI, apolipoprotein AIV, vitronectin, and
plasminogen
CSF and serum levels of apoAI, apoAIV, vitronectin, and
plasminogen were determined in a cohort of 56 CIS
patients, 29 of whom converted to CDMS and 27 who
remained with CIS (cohort 1; Table 1). A control group of
26 patients with other neurological disorders (OND)
was also included in the study (mean age (standard
deviation) = 37.8 (14.2) years; 57.1% females; cohort 1,
Additional file 1: Table S1). Twenty (35.7%) CIS patients
from cohort 1 were also used in the original pooled cohort
[5]. Protein levels were determined by commercially
available ELISA assays. Levels of apoAI were measured
with the ELISAPRO kit for human apolipoprotein AI
(3710-1HP-2; Mabtech AB, Nacka Strand, Sweden) fol-
lowing 1:100 and 1:100000 dilutions in CSF and serum
samples respectively. Levels of apoAIV were measured with
the Human Apolipoprotein AIV ELISA kit (EZHAP0A4-
73 K; Millipore Corporation, Billerica, Massachusetts,
United States) in undiluted CSF samples and following a
1:500 dilution in serum samples. Levels of vitronectin were
quantified with the Human Vitronectin Total Antigen
Assay (HVNKT-TOT; Dunn Labortechnik GmbH, Asbach
Germany) following 1:50 and 1:50000 dilutions in CSF and
serum samples respectively. Levels of plasminogen were
measured with the AssayMax Human Plasminogen ELISA
Kit (EP1200-1; Assaypro, St Charles, Massachusetts, United
States) following 1:100 and 1:20000 dilutions in CSF and
serum samples respectively. All samples were measured in
duplicate. Respective intra-assay and inter-assay variabilities
were 5.3% and 15.0% for apoAI, 6.1% and 21.2% for
apoAIV, 2.8% and 15.2% for plasminogen, and 5.1% and
14.1% for vitronectin.
Quantification of cerebrospinal fluid levels of semaphorin
7A and ala-beta-his-dipeptidase
CSF levels of sema7A and CNDP1 were determined by
SRM in a cohort of 36 CIS patients (18 who converted to
CDMS and 18 who remained as CIS (cohort 2; Table 1)),
and in 20 patients with OND (mean age = 41.4 (15.4);
45% females; cohort 2, Additional file 1: Table S1). Ten
(27.8%) CIS patients from cohort 2 also participated in the
original pooled cohort [5]. CSF samples were precipitated
in acetone overnight at 4°C, solubilized in 6 M urea
(Sigma-Aldrich, St. Louis, MO, USA) in 200 mM ammo-
nium bicarbonate (Sigma-Aldrich, St. Louis, MO, USA),
reduced with 100 mM dithiothreitol (Sigma-Aldrich, St.
Louis, MO, USA), alkylated with 200 mM iodoacetamide
(Sigma-Aldrich, St. Louis, MO, USA), digested with
endopeptidase Lys-C (Wako Chemicals, Richmond, VA,
USA) (2 M urea in 200 mM ammonium bicarbonate at
37°C for 16 hours) and trypsin (Promega, Madison, WI,
USA) (1 M urea in 200 mM ammonium bicarbonate at37°C for 16 hours). After digestion samples were acidified
with 10% formic acid and desalted in C18 columns
(macro-spin columns, The Nest Group Inc., Southborough,
Massachusetts, United States). Four reference isotopically
labeled peptides at C-terminal lysine (13C6,
15 N2-Lys) or
arginine (13C6,
15 N4-Arg) (they are added as a reference
since they allow the unequivocal identification of the
peptide for the protein of interest) were spiked into the
digested samples, two corresponding to sema7A (IFAVWK;
VYLFDFPEGK) and two to CNDP1 (ALEQDLPVNIK;
HLEDVFSK). Peptides were separated chromatographically
with a nanoLC Eksigen coupled to a Q-Trap mass
spectrometer (5500 Q-Trap ABSCIEX, Framingham,
Massachusetts, United States). Briefly, peptides were
initially trapped in a pre-column Acclaim PepMap 100
(C18, 15 μm, 100 Å, Acclaim PepMap 100 ThermoFisher
Scientific (Waltham, Massachusetts, United States)) and
then separated by reverse-phase chromatography using a
15 cm C18 column (75 μm, Nikkyo Technos Co., Tokyo,
Japan) with a gradient of 2 to 40% of solvent B in 35 mi-
nutes at a flow rate of 300 nL/min. Solvent A: H2O, 0.1%
formic acid; Solvent B: Acetonitrile, 0.1% formic acid.
SRM acquisition was performed using an unscheduled
targeted acquisition method with a dwell time of 20 ms
and a total cycle time of 1.4 seconds. For each peptide, 2
to 4 transitions were monitored for both the endogenous
(light) and the reference (heavy) forms (Additional file 2:
Table S2). SRM data was processed using the Skyline
software v1.4.0 (MacCoss lab open-source software,
Seattle, United States) [6] and data peaks were evaluated
based on retention time, transition intensity rank, and
co-elution of the endogenous and reference peptide.
Validation cohorts
Two additional and totally independent validation cohorts
of CIS patients were used to replicate findings with CSF
apoAI, sema7A and CNDP1. These CIS patients were
classified into non-converters and converters to CDMS
according to the same criteria as described above. CSF
levels of apoAI were determined by ELISA (ELISAPRO kit
for Human apolipoprotein AI; 3710-1HP-2; Mabtech AB,
Nacka Strand, Sweden) in 74 CIS patients recruited at the
Cemcat (27 CIS patients who remained with CIS during
the follow-up period and 47 patients who converted to
CDMS (cohort 3; Table 2)). Fifty individuals with OND
were also included as controls (mean age = 42.9 (18.3);
64.6% females; cohort 3, Additional file 3: Table S3).
The abundance of sema7A and CNDP1 in CSF samples
were determined by SRM using the same parameters as
detailed above in 49 CIS patients recruited at the Hospital
Ramón y Cajal (Madrid, Spain); 24 CIS patients who
converted to CDMS and 25 patients who remained with
CIS during the follow-up period (cohort 4; Table 2).
Twenty-two patients with OND were used as controls
Table 2 Clinical information and CSF characteristics of validation cohorts of CIS patients
Cohort 3* - ELISA studies Cohort 4** - proteomic studies
Characteristics CIS→ CIS CIS→ CDMS P values CIS→ CIS CIS→ CDMS P values
n 27 47 - 25 24 -
Age (years)a 30.5 (7.4) 31.3 (6.6) 0.706 36.5 (12.4) 34.2 (9.3) 0.509
Female/male (% female) 22/5 (81.5) 30/17 (63.8) 0.123 16/9 (64.0) 17/7 (70.8) 0.419
Follow-up time (years)a 4.2 (2.8) 8.8 (3.6) 8.24 × 10−7 3.2 (1.3) 10.7 (16.5) 0.034
Clinical presentation
Optic neuritis 16 (59.3) 15 (31.9) 0.146 8 (32.0) 3 (12.5) 0.333
Brainstem 5 (18.5) 12 (25.5) 4 (16.0) 6 (29.1)
Spinal 3 (11.1) 16 (34.0) 7 (28.0) 10 (41.6)
Others 3 (11.1) 4 (8.5) 6 (24.0) 4 (16.6)
CSF cellsb 0.0 (0.0-2.0) 0.0 (0.0-4.0) 0.250 2.0 (0.0-3.2) 3.0 (1.7-9.5) 0.037
Proteins (mg/dL)b 30.0 (25.7-36.2) 34.0 (27.0-40.0) 0.297 28.0 (25.0-36.0) 30.0 (25.0-40.5) 0.753
*Cohort 3 was used for determination of CSF levels of apolipoprotein AI. **Cohort 4 was used for quantification of CSF levels of semaphorin 7A and ala-beta-his-
dipeptidase. aData are expressed as mean (standard deviation). bData are expressed as median (interquartile range). P values were obtained following comparisons
between CIS→ CIS and CIS→ CDMS patients by means of the chi-square test (gender and clinical presentation) and Mann-Whitney U test (remaining variables).
Proteins (mg/dL) refers to protein concentration in mg/dL. CDMS, clinically definite multiple sclerosis; CIS, clinically isolated syndromes, CSF, cerebrospinal fluid.
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file 3: Table S3). A summary of clinical information
and CSF characteristics of CIS patients included in the
validation cohorts is shown in Table 2.
Statistical methods
Differences in CSF and serum protein levels detected by
ELISA between CIS→CIS and CIS→ CDMS patients,
and between CIS patients and controls with OND, were
evaluated by means of a Mann-Whitney U test. SRM
peak intensities were normalized based on the isotopic-
ally labeled peptide standards and transformed by the
logarithm base 2 and protein-level quantification, and
testing for differential abundance were performed using
a linear mixed-effects model as implemented in software
package SRMstats [7].
Results
Cerebrospinal fluid semaphorin 7A, ala-beta-his-dipeptidase,
and apolipoprotein AI levels in CIS patients who convert
to CDMS
Comparisons of CSF levels for candidate proteins in a
partially independent cohort of CIS patients who con-
verted to CDMS and CIS patients who remained with
CIS revealed statistically significant differences for
apoAI, sema7A, and CNDP1 between both groups of
CIS patients. CSF apoAI levels determined by ELISA
were significantly higher in CIS→CDMS patients than in
CIS→CIS patients (P = 0.043; Figure 1A). On the other
hand, CSF levels of sema7A and CNDP1 determined by
SRM were significantly decreased in CIS→ CDMS
compared with CIS→ CIS (P = 4.4 × 10−10 for sema7A
and P = 0.033 for CNDP1; Figure 1B; Additional file 4:
Table S4). Differences in CSF protein abundance werealso observed following comparisons between CIS→
CDMS patients and controls with OND (P = 3.3 × 10−14
for sema7A and P = 3.6 × 10−9 for CNDP1; Figure 1B;
Additional file 4: Table S4). CSF levels of apoAIV, vitro-
nectin, and plasminogen determined by ELISA were
similar between CIS→ CIS and CIS→ CDMS patients
(Figure 1A).
Levels of apoAI, apoAIV, vitronectin, and plasminogen
were also determined by ELISA in serum samples from
the same cohort of CIS patients. However, no statisti-
cally significant differences were observed for any of the
proteins between CIS patients who converted to CDMS
and CIS patients who remained with CIS (Figure 2).
Validation of semaphorin 7A and ala-beta-his-dipeptidase
as biomarkers associated with conversion to CDMS in
CIS patients
In order to replicate CSF findings with apoAI, sema7A,
and CNDP1, protein levels were also measured in a
totally independent cohort of CIS patients who converted
to CDMS and CIS patients who remained with CIS. As
shown in Figure 3, CSF sema7A and CNDP1 levels were
again found to be significantly decreased in CIS→CDMS
patients compared with CIS→CIS patients (P = 1.2 × 10−4
for sema7A and P = 3.7 × 10−8 for CNDP1; Figure 3;
Additional file 5: Table S5), thus confirming their asso-
ciation with conversion to CDMS. Differences in CSF
CNDP levels were also observed following comparisons
between CIS→ CDMS patients and controls with OND
(P = 2.9× 10−3; Figure 3; Additional file 5: Table S5).
Regarding apoAI, although CSF mean protein levels
were higher in CIS→CDMS patients than in CIS→CIS
patients, differences did not reach statistical significance
(P = 0.187; Figure 3). Analysis of CSF apoAI protein levels
Figure 1 CSF levels of apolipoprotein AI, apolipoprotein AIV, vitronectin, plasminogen, semaphorin 7A, and ala-beta-his-dipeptidase
in a first and partially independent cohort of MS converters and non-converters. (A) Boxplots showing CSF levels of apolipoprotein AI,
apolipoprotein AIV, vitronectin, and plasminogen determined by commercially available ELISAs. (B) Boxplots representing CSF abundance of
CNDP1 and semaphorin 7A determined by selected reaction monitoring. Statistically significant P values are shown in bold. *Indicates that
significant differences were also observed between CIS→ CDMS and controls (P = 3.3× 10−14 for semaphorin 7A and P = 3.6 × 10−9 for ala-beta-his
dipeptidase). CIS→ CIS: CIS patients who did not convert to clinically definite MS during the follow-up period. CIS→ CDMS: CIS patients who
converted to clinically definite MS. C: controls with other neurological disorders. Numbers in parentheses indicate individuals available for analysis.
CDMS, clinically definite multiple sclerosis; CDNP1, ala-beta-his-dipeptidase; CIS, clinically isolated syndromes, CSF, cerebrospinal fluid.
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in the CIS→CDMS group compared with the CIS→CIS
group (Table 2), resulted in a similar non-significant
P value.
Cerebrospinal fluid levels of semaphorin 7A are
negatively associated with the number of T2 lesions at
baseline and during the follow-up period
As a last step, we aimed to correlate sema7A and
CNDP1 findings with MRI abnormalities at baseline and
during the follow-up period in the first cohort of CIS
patients (Table 1). As shown in Figure 4, CSF sema7A
levels negatively correlated with the number of T2 lesions
observed in brain MRI scans performed at baseline and
after one year of follow-up, and CSF protein levels
decreased with an increasing number of T2 lesions. No
significant differences were observed between CSF
CNDP1 levels and the number of T2 lesions (Figure 4).
Similarly, no significant correlations were found be-
tween CSF sema7A or CNDP1 levels and the number
of gadolinium-enhancing lesions at baseline, or with
number of gadolinium-enhancing lesions, number of
new T2 lesions, and the Expanded Disability Status Scale
score at one-year follow-up (data not shown).
Finally, correlations between CSF levels of sema7A
and CNDP1 and CSF characteristics such as IgG index,CSF cells, or protein concentration were not statistically
significant (data not shown).
Discussion
In a previous proteomic study conducted by our group
in pooled CSF samples, levels of apoAI, apoAIV, vitro-
nectin, plasminogen, sema7A, and CNDP1 were found
to be significantly different between CIS patients who
converted to CDMS and patients who remained with CIS
[5]. ApoAI was upregulated in CIS patients who converted
to CDMS in all six CSF pools; apoAIV, vitronectin, and
plasminogen were upregulated in four out of six pools. In
contrast, sema7A and CNDP1 were downregulated in four
out of six pools [5]. In the present study, we aimed to
validate these proteins as biomarkers associated with the
conversion to CDMS in individual CSF samples from CIS
patients. Validation was performed in two stages, with a
first replication study in CIS cohorts that had a partial
overlap with the original pooled CIS cohort used for bio-
marker discovery (36% for cohort 1, 28% for cohort 2),
and a second replication study conducted in CIS cohorts
that were totally independent from the pooled CIS cohort.
For all CIS patients, clinical and radiological criteria used
to classify CIS patients into MS converters and non-
converters were similar to the previous proteomic study
[5]. Given the lack of commercially available ELISA assays
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Figure 2 Serum levels of apolipoprotein AI, apolipoprotein AIV, vitronectin, and plasminogen. Boxplots showing serum protein levels
determined by ELISA in CIS patients who converted to CDMS and CIS who remained with CIS. Outliers are represented with asterisks. Statistically
significant p-values are shown in bold. CIS→ CIS: CIS patients who did not convert to clinically definite MS during the follow-up period. CIS→ CDMS:
CIS patients who converted to clinically definite MS. C: controls with other neurological disorders. Numbers in parentheses indicate individuals available
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p=2.9x10-3
Figure 3 Validation of apolipoprotein AI, semaphorin 7A, and ala-beta-his-dipeptidase as biomarkers associated with conversion to
CDMS in a second and totally independent cohort of CIS patients. Boxplots depicting CSF levels of apolipoprotein AI determined by ELISA,
and CSF abundance of CNDP1 and semaphorin 7A determined by selected reaction monitoring in MS converters and non-converters to MS.
Statistically significant P values are shown in bold. *Indicates that significant differences were also observed between CIS→ CDMS and controls
(P = 2.9 × 10−3). CIS→ CIS: CIS patients who did not convert to clinically definite MS during the follow-up period. CIS→ CDMS: CIS patients who
converted to clinically definite MS. C: controls with other neurological disorders. Numbers in parentheses indicate individuals available for analysis.
CDMS, clinically definite multiple sclerosis; CDNP1, ala-beta-his-dipeptidase; CIS, clinically isolated syndromes, CSF, cerebrospinal fluid.





























































MRI at baseline MRI at 1 year
(15)              (6)              (15) (16)              (3)              (14)
(15)               (6)                (15) (16)              (3)              (14)
Figure 4 CSF semaphorin 7A levels are negatively associated with MRI T2 lesion burden. The number of T2 lesions at baseline and after one
year of follow-up was grouped into three different categories: 0 lesions, between 1 and 9 lesions, or more than 9 lesions. Boxplots show the distribution
of CSF levels of semaphorin 7A and ala-beta-his-dipeptidase among these categories. P values were obtained by means of a Mann-Whitney U test.
Numbers in parentheses indicate individuals available for analysis. CSF, cerebrospinal fluid; MRI, magnetic resonance imaging.
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measured by SRM, a well-accepted sensitive, reproducible,
and specific mass spectrometric technique for protein
quantitation [8].
In the first replication step, three out of six candidates,
apoAI, sema7A, and CNDP1, showed statistically signifi-
cant differences between CIS patients who converted to
CDMS and CIS patients who remained with CIS. In the
second validation step, differences between MS converters
and non-converters only remained significant for sema7A
and CNDP1.One of the most striking differences between MS con-
verters and non-converters were observed for sema7A.
Sema7A belongs to a family of membrane-bound and
soluble proteins with roles in axonal guidance and im-
munomodulatory effects [9]. The decreased CSF levels
of sema7A observed in MS converters may be related to
its role as negative regulator of T-cell activation [10]. In
this context, it has been shown that in sema7A-deficient
mice, experimental autoimmune encephalomyelitis (EAE)
disease course is more severe, EAE pathology is exacer-
bated, and T cells show increased proliferative responses
Cantó et al. Journal of Neuroinflammation 2014, 11:181 Page 8 of 9
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Interestingly, in our study CSF sema7A levels negatively
correlated with the degree of lesion burden observed at
baseline and during the follow-up period, finding that
to be in line with the Czopik et al. study [10] where
sema7A knockout mice showed increased inflammation
and demyelination in the central nervous system compared
with wild-type mice.
CNDP1 is a dipeptidase mainly expressed in the liver
and brain that belongs to the M20 metalloprotease family
[11]. CNDP1 hydrolyzes carnosine, which is known to
have neuroprotective effects due to its capacity to decrease
oxidative stress and inflammation [12-14]. Lower CSF
levels of CNDP1 have been reported in MS patients com-
pared with individuals with other neurological diseases
[15], and a decrease in enzyme activity has been observed
in serum samples from MS patients compared with
healthy donors [16]. The lower CSF CNDP1 levels in CIS
patients who later convert to CDMS may be associated
with an increase in the levels of carnosine, which can be
indirectly interpreted as an attempt to protect the brain
from oxidative stress associated with higher inflammation
in MS converters. However, the role of CSF CNDP1 in
these patients needs further investigation, especially con-
sidering the lack of negative association observed in our
study between inflammatory MRI abnormalities such as
the number of gadolinium-enhancing lesions or T2 lesions
and CSF CNDP1 levels.
Finally, the remaining proteins, (apoAI, apoAIV, vitro-
nectin, and plasminogen) which were also proposed as
candidate CSF biomarkers in the initial pooled proteomic
study [5] were not validated in individual CSF samples
using a different technique. Only apoAI, a specific inhibitor
of proinflammatory cytokines secreted by activated T-cells
[17], was found to be significantly increased in CSF from
MS converters, but failed later validation in a totally inde-
pendent cohort of CIS patients. Protein determinations in
serum samples resulted in similar negative results. These
proteins should therefore be considered as false positives
found in the initial discovery proteomic approach [5].
Results from the present study validate two proteins,
sema7A and CNDP1, as biomarkers associated with
conversion to CDMS in CIS patients. These findings
warrant further studies to investigate a potential associ-
ation between decreased CSF levels of sema7A and
CNDP1 and conversion to MS in CIS patients.
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